Preventing crosstalk between the CYP-sEH and COX pathways could account for the beneficial effects of treating PyMT mice lacking Cyp2c44 with celecoxib [16], as well as the benefits of dual sEH and COX inhibition on tumor growth and metastasis [46]. Here, EPHX2 is linked to neoplasm.